1,792 search results for “thijs werkt e2 80 99s discovery” in the Public website
-
Thijs Bonenkamp
Faculty Governance and Global Affairs
t.h.bonenkamp@fgga.leidenuniv.nl | +31 6 4810 5206
-
Thijs Loggen
ICT Shared Service Centre
m.m.loggen@issc.leidenuniv.nl | +31 71 527 5731
-
Thijs Lemaire
Faculteit Rechtsgeleerdheid
p.m.lemaire@law.leidenuniv.nl | +31 71 527 2727
-
Thijs de With
ICT Shared Service Centre
j.m.de.with@issc.leidenuniv.nl | +31 71 527 2727
-
Thijs Aartsma
Science
aartsma@physics.leidenuniv.nl | +31 71 527 5967
-
Thijs Bierman
Science
t.v.bierman@biology.leidenuniv.nl | +31 71 527 2727
-
Thijs Hoogenboom
Science
hoogenboom@physics.leidenuniv.nl | +31 71 527 1897
-
Thijs Voskuilen
Science
t.voskuilen@lic.leidenuniv.nl | +31 71 527 4516
-
Thijs Stockmans
Science
stockmans@strw.leidenuniv.nl | +31 71 527 2727
-
Thijs Bos
Science
j.m.bos@math.leidenuniv.nl | +31 71 527 2727
-
Thijs Bosker
Science
t.bosker@cml.leidenuniv.nl | +31 71 527 4924
-
Thijs Witty
Faculty of Humanities
t.witty@hum.leidenuniv.nl | +31 71 527 2727
-
Thijs Vos
Faculteit der Sociale Wetenschappen
t.j.vos@fsw.leidenuniv.nl | +31 71 527 2727
-
Thijs Porck
Faculty of Humanities
m.h.porck@hum.leidenuniv.nl | +31 71 527 1611
-
Thijs van Osch
Faculteit Geneeskunde
m.j.p.van_osch@lumc.nl | +31 71 526 9111
-
Thijs van Veen
Universitair Facilitair Bedrijf
t.van.veen@ufb.leidenuniv.nl | +31 71 527 4231
-
Thijs van den Berg
Faculteit der Sociale Wetenschappen
t.s.van.den.berg@fsw.leidenuniv.nl | +31 71 527 2727
-
Thijs van Dooremalen
Faculty Governance and Global Affairs
t.j.a.van.dooremalen@fgga.leidenuniv.nl | +31 70 800 9500
-
Thijs van Kolfschoten
Faculteit Archeologie
t.van.kolfschoten@arch.leidenuniv.nl | +31 71 527 2640
-
Thijs Brocades Zaalberg
Faculty of Humanities
t.w.brocades.zaalberg@hum.leidenuniv.nl | +31 71 527 2770
-
Thijs de Boer
Faculty Governance and Global Affairs
t.c.de.boer@fgga.leidenuniv.nl | +31 70 800 8206
-
Thijs Jan van Schie
Faculteit der Sociale Wetenschappen
t.j.van.schie@fsw.leidenuniv.nl | +31 71 527 3451
-
Cryptic species discovery
Do understudied animals contain hidden species?
-
Hit Discovery
The goal of hit discovery is to identify suitable chemical starting points to modulate a drug target. A hit can be, a.o., a small molecule, a protein or mRNA. Hit identification is performed via rational design, genome mining, (targeted) library screening, or in silico approaches.
-
Target Discovery
The goal of target discovery is to identify and validate proteins and biological pathways that are involved in the disease process. Modulating these target proteins and pathways with small molecules, therapeutic proteins or other biomolecules (e.g. mRNA) could deliver an effective and safe drug or v…
-
Leiden discoveries
From the Big Bang to superconductivity. Many ground-breaking discoveries have been made in Leiden University’s long history.
-
Discoveries in 2023
From nanoparticles to colliding ice planets and from biological origami to new x-ray scanner techniques: this year again, our scientists have made wonderful discoveries. From the largest numbers to the smallest molecules and from the oldest galaxies up to the latest algorithms, take a look at each institute's…
-
Data-Driven Drug Discovery Network (D4N)
The Data-Driven Drug Discovery Network (D4N) is an initiative by researchers from Leiden University and collaborators to join efforts in applying and developing novel techniques from data science to drug discovery and related topics from bioinformatics.
-
Drug discovery pipeline
The drug discovery pipeline is used to describe the stages in drug discovery. The earliest stage concerns with the identification of potential targets and molecules ('hits') that can modulate their function, while more advanced stages are about developing these hits into viable experimental drugs and…
-
Night of Discoveries
The Night of Discoveries is an annual event in Leiden, focusing on science and culture. The Young Academy Leiden is a recurring contributor to the Night of Discoveries.
-
Computational Drug Discovery
Research in this group, headed by Gerard van Westen, focusses on computational methods integrated in different parts of the drug discovery process. More specifically, topics include innovative treatments for cancer, selectivity modeling, translational research, allosteric modulation, drug resistance…
-
Drug Discovery & Safety
In the research programme Drug Discovery & Safety, we are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.
-
Modern Drug Discovery
How are new drugs developed? This question is central to the Minor Modern Drug Discovery (MDD), which covers the entire trajectory from disease to drug molecule and vice versa. The various research groups involved offer a complementary and interdisciplinary perspective by connecting the diverse subjects…
-
Cancer Drug Target Discovery
We focus on a better understanding of the mechanisms of cancer drug resistance and metastasis.
-
Cancer Drug Target Discovery
In this research group, headed by Prof. Erik Danen, the aim is to unravel cellular signaling mechanisms in normal and diseased cells, with a long-standing interest in cell adhesion signaling. In complex multicellular organisms such as ourselves, a division of labor emerges where different tissues and…
-
Drug Discovery and Safety (MSc)
The master's specialisation Drug Discovery and Safety at Leiden University provides students with research-oriented education into the discovery of new drug targets and new lead molecules, particularly in the field of cancer, through a combination of advanced imaging techniques (‘systems microscopy’),…
-
Leiden Early Drug Discovery & Development
Despite recent advances in medicine, many devastating disorders like cancer and cardiovascular, neurodegenerative and infectious diseases still lack effective treatments. In order to address this challenge, we, as scientists from Leiden University, joined hands in the LED3 network. LED3, for Leiden…
-
LED3 Drug Discovery Case Studies
To get a feeling of how we operate at LED3 when it comes to Early Drug Discovery, please browse through our case studies. When you select a case study you’ll find relevant contacts.
-
Translational drug discovery and development
We cover the entire spectrum from target identification to the evaluation of the efficacy and safety of novel medicines in clinical practice.
-
LED3 Lecture: Computational Drug Discovery
Lecture
-
LED3 Lecture: Covalent Drug Discovery
Lecture
-
Discovery of metastasis promoting candidate drug targets
Discovery of metastasis promoting candidate drug targets
-
Activity-based protein profiling in drug discovery
In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.
-
Inhibitor discovery of phospholipases and N-acyltransferases
In this thesis an activity-based probe was discovered that could visualize the activity of PLAATs. With an optimized gel-based ABPP assay in hand, screening of a compound library led to the discovery of alpha-ketoamides as a hit for PLAAT3.
-
Discovery of antibiotics and their targets in multidrug-resistant bacteria
Global healthcare is on the verge of an antibiotic availability crisis as bacteria have evolved resistance to nearly all known antibacterials. Identifying new antibiotics that operate via novel modes-of-action is therefore of high priority.
-
Kinetics for drug discovery – The first step towards an improved drug discovery paradigm
Supervisor: Indira Nederpelt
-
PhD candidate combinatorial drug discovery with macrocycles
Science, Leiden Academic Centre for Drug Research (LACDR)
-
LED3 Lecture: Chemical Biology for Drug Discovery
Lecture
-
LED3 Lecture: Data Science in Drug Discovery
Lecture
-
LED3 Lecture: Proteomics in Drug Discovery
Lecture